ASGCT 2025 | BioAgilytix

Continuing our CGT insights discussions here at ASGCT 2025, we had the pleasure of speaking with Jessica Bridges Weaver, Scientific Officer with BioAgilytix.

From FDA strategies for potency assurance to the reality of developing robust CMC methods—Jessica shared numerous insights on where the field is headed and what to look out for. Topics we discussed include:

🔬 Innovations in gene and cell therapy
🧪 BioAgilytix’s consultative, science-driven approach to CMC testing
🧩 Big challenges the industry must solve in the next 5 years
🚀 Their team’s proudest moments helping bring rare disease therapies to patients